Chief executive of Array BioPharma resigns

Chairman Kyle Lefkoff will lead effort to replace Robert Conway

Robert Conway has resigned as chief executive of Array BioPharma, a US biotechnology company, for personal reasons. The board has appointed chairman Kyle Lefkoff to serve as executive chairman to oversee the company in the interim and lead the effort to identify a new chief executive.

Lefkoff said he will work with the Array management team to ensure a smooth transition and continued advancement of the company’s multiple clinical programmes in cancer and inflammation and supporting our many partnered programmes.

You may also like

Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Finance

Array BioPharma to cut jobs in restructure

Will focus on development of key clinical programmes
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
Formulation freedom in clinical development: Why Fill2Weight matters

Formulation freedom in clinical development: Why Fill2Weight matters

As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Media
Plan your marketing strategy with Manufacturing Chemist

Plan your marketing strategy with Manufacturing Chemist

Discover upcoming special reports, themed features and commercial opportunities to help you connect with pharmaceutical manufacturing decision-makers throughout the year
Research & Development
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Subscribe now